Novo Nordisk Reports Cyberattack Leading to Theft of Clinical Trial Data
Pharmaceutical giant Novo Nordisk has disclosed a cyberattack resulting in the unauthorized access and exfiltration of sensitive clinical trial data. The incident comes as the UK approves its Wegovy pill, highlighting the increasing vulnerability of healthcare and pharmaceutical sectors to sophisticated cyber threats. The breach of clinical trial data could have significant implications for patient privacy, intellectual property, and regulatory approvals. Organizations must reinforce their cybersecurity posture to protect highly sensitive health information.